FacebookTwitterGoogle+RedditEmail

Big Pharma Has A Rare Week

by MARTHA ROSENBERG

The sound you hear is Pharma swinging from the rafters. Two news stories this week may reinfuse revenue streams in an industry whose blockbuster pill “bubble” has burst.  As Lipitor, Seroquel, Zyprexa, Singulair, Concerta and several other drugs have lost patent protection, Pharma is shedding both employees and ad campaigns. WebMD, the voice of Pharma on the Web, announced it would cut 250 positions in December and medical journals like the Journal of the American Medical Association (JAMA) and New England Journal of Medicine are noticeably thinner without the Pharma ads that have leavened them for years.

Vitamin D and calcium will not protect older women from fractures, a government task force reported this week, in the Annals of Internal Medicine. The U.S. Preventive Services Task Force “recommends against daily supplementation with 400 IU or less of vitamin D3 and 1000 mg or less of calcium for the primary prevention of fractures” and  also recommends that older women, and younger ones with risk factors, be screened for osteoporosis.

While the report does not recommend expensive drugs or seem to be penned by Pharma consultants, its message is still good news for Pharma whose anti-osteoporosis drugs carried it through the 2000s.  “Don’t rely on just Vitamin D and calcium” and “get a bone scan!” were the marketing messages of the bone drugs Boniva, Fosamax and Actonel.

According to published reports, Merck, who launched the bone drug category with its Fosamax, single handedly initiated the “bone scan” craze foisted on middle aged and older women, including setting up a bone “institute” to secure Medicare reimbursement for the scans which were driving Fosamax sales.

Pharma even created the term “osteopenia”–at risk of osteoporosis–to sell the now discredited bone drugs, which are linked to esophageal cancer, osteonecrosis of the jaw, irregular heart beat, pain and actually causing fractures. Subsequent medical reports found the heavily marketed bone scans only benefit 10 percent of women who get them.

In more good news for Pharma this week, Genentech’s drug for allergic asthma, Xolair, co-marketed with Novartis, was trumpeted as having a new possible indication of treating patients with chronic hives or chronic idiopathic urticaria, reported the New York Times. If approved for the new indication, chronic idiopathic urticaria will likely became a major U.S. health problem to be advertised on TV like restless legs syndrome. Ka-ching.

Genetically engineered drugs like Xolair (called monoclonal antibodies) cost as much as $20,000 a year and cause TB, cancers and super infections according to their labels because they suppress the immune system. Xolair was investigated by the FDA for links to heart attack and stroke and 77 people who took Xolair had life-threatening allergic responses in a year and a half, according to FDA reports.

Some of the clinical tests to determine Xolair’s safety were conducted at Vivra which was investigated twice by the FDA for procedural irregularities. Trials of Xolair and at least seven other drugs were corrupted by protocol violations and outright falsifications, according to a former clinical research subinvestigator who worked at the facility. San Mateo, Calif.-based Vivra Asthma & Allergy was the nation’s largest respiratory disease physician practices until a merger with Lakewood, Colo.-based Gambro in 1997 and with El Segundo, Calif.-based DaVita in 2005.

There is even a genetically engineered monoclonal antibody drug called Prolia to treat osteoporosis that costs $1,650 a year now that we know Vitamin D and calcium don’t work.

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

February 10, 2016
Eoin Higgins
Clinton and the Democratic Establishment: the Ties That Bind
Fred Nagel
The Role of Legitimacy in Social Change
Mike Whitney
Putin’s Aleppo Gamble Pays Off
Ramzy Baroud
Next Onslaught in Gaza: Why the Status Quo Is a Precursor for War
Sheldon Richman
End, Don’t Extend, Draft Registration
Benjamin Willis
Obama in Havana
Jack Smith
Obama Intensifies Wars and Threats of War
Rob Hager
How Hillary Clinton Co-opted the Term “Progressive”
Mark Boothroyd
Syria: Peace Talks Collapse, Aleppo Encircled, Disaster Looms
Lawrence Ware
If You Hate Cam Newton, It’s Probably Because He’s Black
Jesse Jackson
Starving Government Creates Disasters Like Flint
Bill Laurance
A Last Chance for the World’s Forests?
Gary Corseri
ABC’s of the US Empire
Chris Martenson
The Return of Crisis: Everywhere Banks are in Deep Trouble
Frances Madeson
The Pain of the Earth: an Interview With Duane “Chili” Yazzie
Binoy Kampmark
The New Hampshire Distortion: The Primaries Begin
Andrew Raposa
Portugal: Europe’s Weak Link?
Wahid Azal
Dugin’s Occult Fascism and the hijacking of Left Anti-Imperialism and Muslim Anti-Salafism
February 09, 2016
Andrew Levine
Hillary Says the Darndest Things
Paul Street
Kill King Capital
Ben Burgis
Lesser Evil Voting and Hillary Clinton’s War on the Poor
Paul Craig Roberts
Are the Payroll Jobs Reports Merely Propaganda Statements?
Fran Quigley
How Corporations Killed Medicine
Ted Rall
How Bernie Can Pay for His Agenda: Slash the Military
Neve Gordon
Israeli Labor Party Adopts the Apartheid Mantra
Kristin Kolb
The “Great” Bear Rainforest Agreement? A Love Affair, Deferred
Joseph Natoli
Politics and Techno-Consciousness
Hrishikesh Joshi
Selective Attention to Diversity: the Case of Cruz and Rubio
Stavros Mavroudeas
Why Syriza is Sinking in Greece
David Macaray
Attention Peyton Manning: Leave Football and Concentrate on Pizza
Arvin Paranjpe
Opening Your Heart
Kathleen Wallace
Boys, Hell, and the Politics of Vagina Voting
Brian Foley
Interview With a Bernie Broad: We Need to Start Focusing on Positions and Stop Relying on Sexism
February 08, 2016
Paul Craig Roberts – Michael Hudson
Privatization: the Atlanticist Tactic to Attack Russia
Mumia Abu-Jamal
Water War Against the Poor: Flint and the Crimes of Capital
John V. Walsh
Did Hillary’s Machine Rig Iowa? The Highly Improbable Iowa Coin Tosses
Vincent Emanuele
The Curse and Failure of Identity Politics
Eliza A. Webb
Hillary Clinton’s Populist Charade
Uri Avnery
Optimism of the Will
Roy Eidelson Trudy Bond, Stephen Soldz, Steven Reisner, Jean Maria Arrigo, Brad Olson, and Bryant Welch
Preserve Do-No-Harm for Military Psychologists: Coalition Responds to Department of Defense Letter to the APA
Patrick Cockburn
Oil Prices and ISIS Ruin Kurdish Dreams of Riches
Binoy Kampmark
Julian Assange, the UN and Meanings of Arbitrary Detention
Shamus Cooke
The Labor Movement’s Pearl Harbor Moment
W. T. Whitney
Cuba, War and Ana Belen Montes
Jim Goodman
Congress Must Kill the Trans Pacific Partnership
FacebookTwitterGoogle+RedditEmail